Prevention and Treatments of Age-Related Macular Degeneration

Dear Colleagues,

Age-related macular degeneration remains the leading cause of visual impairment in those over 60 years of age. To date, anit-vegf therapies for late-stage disease, the neovascular subtype, have been used to treat the disease, but they are not a cure. There is currently no treatment for the other end-stage of AMD, the geographic atrophic (GA) subtype, or the intermediate or earlier forms of AMD. Current understanding of local disease pathophysiology in AMD is limited. Moreover, whether or not some aspects of AMD are localized, systemic or a combination of both is also unclear. There is no animal model which faithfully recapitulates the clinical spectrum of AMD. Therefore, understanding AMD disease mechanisms or the functional consequence of associated genetic variation can be challenging. In vitro assays can complement in vivo models, and many groups are currently working to develop such assays. Studies that incorporate standardized phenotyping of source material (DNA, RNA, and/or protein) coupled with in vitro and/or in vivo assays would help in the development of novel translational treatment and prevention options, particularly for earlier forms of AMD.

Prof. Dr. Margaret M. DeAngelis
Prof. Dr. Lindsay A. Farrer
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.